Open Access

RBBP7 is a prognostic biomarker in patients with esophageal squamous cell carcinoma

  • Authors:
    • Ning Yu
    • Peng Zhang
    • Li Wang
    • Xinjia He
    • Shanshan Yang
    • Haijun Lu
  • View Affiliations

  • Published online on: October 3, 2018     https://doi.org/10.3892/ol.2018.9543
  • Pages: 7204-7211
  • Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Retinoblastoma‑binding protein 7 (RBBP7) is an important component of several complexes that regulate chromatin metabolism. It is overexpressed in certain cancer types and serves conflicting roles in tumor progression. In the present study, the expression and roles of RBBP7 were explored in esophageal squamous cell carcinoma (ESCC). Immunohistochemical staining was used to detect RBBP7 expression in ESCC tissues. The mRNA sequencing profiles from the Cancer Genome Atlas and Genotype‑Tissue Expression databases were mined to analyze the mRNA expression of RBBP7 in tissues. Proliferation, clone formation, apoptosis and Transwell invasion/migration assays were performed to explore the roles of RBBP7 in ESCC. RBBP7 was highly expressed in ESCC tissues. The protein and mRNA expression levels of RBBP7 were significantly elevated in tumor tissues compared with paired adjacent normal tissues. RBBP7 overexpression was associated with a poor overall survival in patients with ESCC. Furthermore, higher RBBP7 expression was significantly correlated with poor tumor differentiation, advanced regional lymph node involvement, and pathological TNM staging. Knockdown of RBBP7 in ESCC cells did not affect tumor apoptosis or tumor growth. However, the overexpression of RBBP7 significantly enhanced the invasion and migration of ESCC cells, whereas the knockdown of RBBP7 resulted in significantly decreased invasion and migration. The present study indicated that RBBP7 is a novel biomarker and prognosticator for patients with ESCC. Furthermore, RBBP7 serves crucial roles in promoting ESCC invasion and migration.
View Figures
View References

Related Articles

Journal Cover

December-2018
Volume 16 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yu N, Zhang P, Wang L, He X, Yang S and Lu H: RBBP7 is a prognostic biomarker in patients with esophageal squamous cell carcinoma. Oncol Lett 16: 7204-7211, 2018
APA
Yu, N., Zhang, P., Wang, L., He, X., Yang, S., & Lu, H. (2018). RBBP7 is a prognostic biomarker in patients with esophageal squamous cell carcinoma. Oncology Letters, 16, 7204-7211. https://doi.org/10.3892/ol.2018.9543
MLA
Yu, N., Zhang, P., Wang, L., He, X., Yang, S., Lu, H."RBBP7 is a prognostic biomarker in patients with esophageal squamous cell carcinoma". Oncology Letters 16.6 (2018): 7204-7211.
Chicago
Yu, N., Zhang, P., Wang, L., He, X., Yang, S., Lu, H."RBBP7 is a prognostic biomarker in patients with esophageal squamous cell carcinoma". Oncology Letters 16, no. 6 (2018): 7204-7211. https://doi.org/10.3892/ol.2018.9543